Cartesian Therapeutics Highlights Progress and 2024
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track...
Source: globenewswire.com
Carsten Brunn News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Carsten Brunn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Carsten Brunn Today - Breaking & Trending Today
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
Topline data from Phase 2b study of Descartes-08, the Company’s potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis remains on track for mid-2024 Positive 12-month...
Source: marketscreener.com
Selecta Biosciences Announces Merger with Cartesian Therapeutics
13.11.2023 - – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian’s wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses ... Seite 1
Source: wallstreet-online.de
Selecta Biosciences Merges With Cartesian Therapeutics In All-stock Deal
Selecta Biosciences, Inc. (SELB) announced Monday that it has merged with biotechnology company Cartesian Therapeutics, Inc. In connection with the merger, Selecta announced a $60.
Source: rttnews.com
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
31.10.2023 - WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) - Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, ... Seite 1
Source: wallstreet-online.de